North Rock Partners, LLC Vericel Corp Transaction History

North Rock Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$22.88 - $39.45 $125,794 - $216,896	-5,498 Closed	0 $0
Q1 2022 May 05, 2022	BUY	$31.69 - $43.29 $95 - $129	3 Added 0.05%	5,498 $210,000
Q4 2021 Feb 07, 2022	BUY	$35.2 - $52.6 $739 - $1,104	21 Added 0.38%	5,495 $216,000
Q3 2021 Nov 12, 2021	BUY	$46.35 - $59.75 $278 - $358	6 Added 0.11%	5,474 $267,000
Q2 2021 Aug 12, 2021	BUY	$47.2 - $67.81 $1,935 - $2,780	41 Added 0.76%	5,468 $287,000
Q1 2021 May 11, 2021	BUY	$30.93 - $59.48 $167,857 - $322,797	5,427 New	5,427 $301,000
Q1 2019 May 14, 2019	SELL	$16.23 - $20.29 $452,395 - $565,563	-27,874 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$10.77 - $18.44 $300,202 - $513,996	27,874 New	27,874 $485,000

268

48.4M

91.1K

39.8K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.04B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of North Rock Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on North Rock Partners, LLC with notifications on news.